Morpholinyl Amine Compounds Targeting TLR7/8/9 for Autoimmune Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for autoimmune diseases like systemic lupus erythematosus (SLE) and lupus nephritis are inadequate, with existing treatments being either ineffective or associated with significant toxicity and side effects, and there is a lack of effective, steroid-free, and non-cytotoxic oral drugs targeting Toll-like receptors (TLR7/8/9, which are key nodes in autoimmune and auto-inflammatory diseases.
Innovation Solution
Development of novel organic compounds that act as antagonists for TLR7, TLR8, and TLR9, specifically designed to inhibit these receptors, offering superior antagonism activity, good cytotoxicity, solubility, human microsome stability, and low CYP inhibition, thereby providing a therapeutic option for SLE and lupus nephritis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If traditional nonspecific anti-inflammatory or immunosuppressive drugs are used to treat SLE, then broad inflammation and tissue damage can be suppressed, but long term usage is associated with undesirable toxicity and side effects
Solution Approach 1:
The patent segments the broad immunosuppressive effect into specific targeted inhibition of TLR7, TLR8, and TLR9 pathways. Instead of suppressing the entire immune system, the invention selectively blocks the specific nucleic acid sensing pathways that are aberrantly activated in SLE, thereby reducing inflammation while preserving overall immune function and minimizing toxicity.
Solution Approach 2:
The patent introduces small molecule compounds as intermediaries that specifically bind to and inhibit TLR7, TLR8, and TLR9 receptors. These compounds act as mediators between the aberrant nucleic acid sensing and the downstream immune response, blocking the harmful signaling pathway while allowing other immune functions to proceed normally.
2Reliability
If Belimumab is used to treat SLE, then some patients can achieve disease control, but efficacy is modest and delayed, and it only works in a fraction of patients
Solution Approach 1:
The patent employs preliminary action by directly blocking TLR7, TLR8, and TLR9 receptors before aberrant nucleic acid sensing can trigger downstream inflammatory cascades. This upstream inhibition prevents the activation of multiple downstream pathways simultaneously, leading to faster and more reliable disease control compared to therapies that act downstream in the inflammatory pathway.
Solution Approach 2:
The patent changes the therapeutic parameter from targeting downstream inflammatory mediators (as with Belimumab) to targeting upstream pattern recognition receptors. By altering the point of intervention in the disease pathway to TLR7/8/9 inhibition, the therapy achieves more consistent and rapid efficacy across a broader patient population.
3Reliability
If TLR7/8/9 inhibition is implemented to treat autoimmune diseases, then sustained improvement can be achieved in a greater proportion of patients, but the complexity of selectively inhibiting these receptors increases
Solution Approach 1:
The patent applies universality by designing small molecule compounds that can simultaneously inhibit multiple TLRs (TLR7, TLR8, and TLR9) with a single agent. This multi-functional approach simplifies the therapeutic regimen while maintaining selectivity for the specific nucleic acid sensing pathways, achieving sustained improvement without requiring complex combination therapies.
Solution Approach 2:
The patent uses composite molecular structures that combine pharmacophores capable of binding to different TLRs. The compounds feature specific structural elements (such as heterocyclic rings and basic nitrogen atoms) that enable simultaneous interaction with TLR7, TLR8, and TLR9, achieving broad selectivity through molecular composite design.
4Object-affected harmful factors
If oral compounds targeting TLR7/8/9 are developed, then effective steroid-free treatment can be provided, but the compounds must achieve superior antagonism activity, good cytotoxicity profile, and low CYP inhibition simultaneously
Solution Approach 1:
The patent optimizes multiple molecular parameters simultaneously to achieve the desired profile: adjusting basic nitrogen content and aromatic ring structures to enhance TLR antagonism activity, modifying solubility parameters through specific substituent patterns, and tuning metabolic stability by controlling CYP inhibition through molecular structure design. This multi-parameter optimization enables oral compounds to meet all performance requirements.
Solution Approach 2:
The patent employs composite molecular structures that integrate multiple functional elements: heterocyclic aromatic rings for TLR binding, basic nitrogen atoms for receptor interaction, and specific substituent patterns for optimizing solubility and metabolic stability. These composite structures achieve superior antagonism activity, good cytotoxicity profile, and low CYP inhibition simultaneously.
Data Source
AI summary
The present invention relates to compounds of formula (I), wherein R1, R2 and R3 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.